Evaluation of Relationship between Modified ATRIA Risk Score and Mortality in Hospitalized Patients with COVID-19

Yıl 2023, Cilt: 5 Sayı: 1, 107 - 14, 15.01.2023

Abdulmecit Afşin , Kasım Turgut , Nurbanu Bursa , Erdal Yavuz , Taner Güven , Yusuf Hoşoğlu

https://doi.org/10.37990/medr.1176092

https://izlik.org/JA86KE72UZ

Öz

Aim: The ATRIA score was developed to assess the probability of an ischemic stroke in patients with atrial fibrillation (AF). The modified ATRIA (M-ATRIA) risk score incorporates predictive risk variables for coronavirus disease 2019 (COVID-19). As a result, we looked into the association between the M-ATRIA risk score and the risk of in-hospital death in COVID-19 patients.
Materials and Methods: The data of 595 inpatients in the COVID-19 research were evaluated retrospectively and separated into three groups based on the M-ATRIA scoring system. The M-ATRIA score used the troponin I level as a parameter in place of the proteinuria criterion in the ATRIA score. Those with a score between 0 and 5 were classified as group 1 (n = 269), those with a score of 6 as group 2 (n = 64), and those with a score of 7 and above were classified as group 3 (n = 162). In-hospital death, mechanical ventilation, and admission to the critical-care unit were all considered adverse clinical events.
Results: The M-ATRIA risk score associated with adverse clinical events (all, p < 0.001). An M-ATRIA score of 6, an M-ATRIA score greater than 7, procalcitonin, and C- reactive protein were found to be independent predictors of in-hospital mortality in the multivariate logistic regression analysis. In the ROC analysis, an M-ATRIA score of 4.5 or above predicted in-hospital mortality with a sensitivity of 90.2% and a specificity of 58.9%.
Conclusion: Regardless of the status of AF, the M-ATRIA risk score computed at admission may be a valuable tool for predicting in-hospital mortality in COVID-19 patients.

Anahtar Kelimeler

coronavirus disease 2019 , M-ATRIA risk score , intensive care unit , in-hospital mortality.

Kaynakça

• 1. Xu S, Huang R, Sy LS, et al. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1520-24.
• 2. Godoy LC, Goligher EC, Lawler PR, et al. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. CMAJ. 2020;192:E1156-61.
• 3. Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2:e000250.
• 4. Van Den Ham HA, Klungel OH, Singer DE, et al. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores 3209in patients with atrial fibrillation in a national primary care database and the impact on treatment decisions. J Am Coll Cardiol. 2015;66:1851-9.
• 5. Cetinkal G, Kocas BB, Ser OS, et al. Assessment of the Modified CHA2DS2VASc Risk Score in Predicting Mortality in Patients Hospitalized With COVID-19. Am J Cardiol. 2020;135:143-9.
• 6. Quisi A, Alıcı G, Harbalıoğlu H, et al. The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: A multicenter retrospective cohort study. Turk Kardiyol Dern Ars. 2020;48:656-63.
• 7. Al Abbasi B, Torres P, Ramos-Tuarez F, et al. Cardiac Troponin-I and COVID-19: A Prognostic Tool for In-Hospital Mortality. Cardiol Res. 2020;11:398-404.
• 8. The Republic of Turkey Ministry of Health. COVID-19 (SARS-CoV-2 Infection) (Study of Scientific Board) General Information, Epidemiology and Diagnosis.2020. Website https://covid19.saglik.gov.tr/Eklenti/39061/0/covid-19rehberieriskinhastatedavisipdf.pdf accessed date 9 November 2020
• 9. Armstrong RA, Kane AD, Kursumovic E, et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021;76:537-48.
• 10. Cohen JF, Korevaar DA, Matczak S, et al. COVID-19–Related Fatalities and Intensive-Care-Unit Admissions by Age Groups in Europe: A Meta-Analysis. Front.Med. 2021;7:560685.
• 11. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020;188:109890.
• 12. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020;21:915-8.
• 13. Ruocco G, McCullough PA, Tecson KM, et al. Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. Am J Cardiol 2020;137:111-7.
• 14. Ozturk S, Turgut alp K, Arici M, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant. 2020;35:2083-95.
• 15. Aciksari G, Cetinkal G, Kocak M, et al. Evaluation of Modified ATRIA Risk Score in Predicting Mortality in Hospitalized Patients with COVID-19. Am J MedSci. 2021;S0002-9629:00214-7.
• 16. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: an early systematic review and meta-analysis. Trop Med Infect Dis. 2020;5:80.
• 17. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13:1833-9.
• 18. Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes. 2020;12:895-908.
• 19. Gerotziafas GT, Catalano M, Colgan MP, et al. Scientific Reviewer Committee. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. ThrombHaemost. 2020;120:1597-628.
• 20. Caro-Codón J, Lip GYH, Rey JR, et al. Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19. Europace. 2021;23:937-97.
• 21. Cheruiyot I, Kipkorir V, Ngure B, et al. Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review. Ann Vasc Surg. 2021;70:273-81.
• 22. Di Minno A, Ambrosino P, Calcaterra I, et al. COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. SeminThromb Hemost. 2020;46:763-71.
• 23. Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639.
• 24. Liang W, Liang H, Ou L, et al. China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med. 2020;180:1081-9.
• 25. Acar HC, Can G, Karaali R, et al. An easy-to-use nomogram for predicting in-hospital mortality risk in COVID-19: a retrospective cohort study in a university hospital. BMC Infect Dis. 2021;21:148.
• 26. El-Solh AA, Lawson Y, Carter M, et al. Comparison of in-hospital mortality risk prediction models from COVID-19. PLoS ONE. 2020;15:e0244629.